Lamellar has a focus on rare diseases where there is high unmet clinical need. Non-clinical development has provided excellent results demonstrating the potential of LAMELLASOME™ technology in the orphan drug areas of IPF and CF. Lamellar will undertake non-clinical development shortly in these indications while submitting worldwide patents. While focussing on IPF and CF, it is clear that LAMELLASOME™ technology can be applied to other serious and rare diseases.
These products advance novel treatments for rare diseases where there is high unmet clinical need.